文献速递慢性肾脏病血液净化与透析肾移植

聚焦衰弱:肾脏病 aging 研究协作组衰弱评估工具的范围综述

Frailty in Focus: A Scoping Review of Frailty Instruments from the Kidney Disease Aging Research Collaborative.
PubMed 文献 · Clin J Am Soc Nephrol · 2026-01-21

该范围综述系统检索了截至2024年9月的多个数据库,纳入136篇在肾脏病人群中应用除身体衰弱表型外经验证衰弱工具的研究。临床衰弱量表(CFS)心理测量学效度最强,多数工具对死亡和住院有预测效度,但现有工具未全面覆盖心理社会和生理领域。

要点

  • 除身体衰弱表型外,临床衰弱量表在肾脏病中效度最强。
  • 多数衰弱工具对肾脏病人群死亡和住院具有预测效度。
  • 现有工具未全面覆盖衰弱心理社会和生理领域,需进一步验证。

核心结论

  • 除身体衰弱表型外,临床衰弱量表效度最强,但可能高估衰弱患病率。

研究设计与样本

  • 遵循范围综述指南,检索PubMed、EMBASE、Cochrane、CINAHL、Web of Science、ClinicalTrials.gov和PsycInfo从建库至2024年9月。
  • 初检4048条结果,最终纳入136篇在肾脏病人群中应用除身体衰弱表型外经验证衰弱工具的研究。

主要发现

  • 最常引用的工具为临床衰弱量表(N=56)、FRAIL量表(N=30)和Edmonton衰弱量表(N=16)。
  • 多数研究纳入接受血液透析的成人(N=85)和慢性肾脏病患者(N=39),中位年龄范围为53-83岁。
  • 多数衰弱工具对死亡和住院表现出预测效度,并发效度常与高龄、女性、更多合并症和较低白蛋白相关。
  • 仅7项研究报告了信度,部分工具(CFS、FRAIL)可行但可能比身体衰弱表型测得更高的衰弱患病率。

临床怎么用

  • 临床可优先考虑使用临床衰弱量表评估肾脏病患者衰弱,但需注意其可能高估患病率。
  • 现有衰弱工具可用于预测死亡和住院风险,但应结合心理社会和生理指标综合评估。

局限性

  • 现有工具未全面覆盖衰弱心理社会和生理领域。
  • 仅少数研究报告信度,年轻成人、急性肾损伤、肾移植受者和保守肾脏管理人群中心理测量学性质有待验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: The clinical frailty scale has the strongest psychometric validity in kidney disease apart from the physical frailty phenotype. Existing frailty instruments have strong predictive validity for mortality and hospitalizations across kidney disease populations. Future work should test validity in younger adults, psychosocial and physiologic domains, and use of frailty instruments as screeners. BACKGROUND: Frailty is a multisystem syndrome of decreased physiologic reserve with high prevalence, early incidence, and prognostic significance in kidney disease. Apart from the physical frailty phenotype (PFP), less is known regarding psychometric properties of other instruments. We critically appraise the validity and reliability of frailty instruments across the kidney disease continuum, acknowledge limitations, and highlight knowledge gaps. METHODS: Following Preferred Reporting Items for Scoping Reviews guidelines, we searched PubMed, EMBASE, Cochrane, Cumulated Index in Nursing and Allied Health Literature, Web of Science, ClinicalTrials.gov, and PsycInfo from website inception through September 2024. Eligible studies applied a validated frailty instrument apart from the PFP to a kidney disease population. RESULTS: We identified 136 articles after screening 4048 initial results. The most commonly cited instruments were the clinical frailty scale (CFS; N=56); Fatigue, Resistance, Ambulation, Illnesses, and Loss of Weight Scale (N=30); and Edmonton frail scale (N=16). Most studies included adults receiving hemodialysis (N=85) and with CKD (N=39). Median age ranges were 53–83 years. Most frailty instruments demonstrated predictive validity for mortality and hospitalizations. Concurrent validity was most frequently demonstrated between frailty and older age, female sex, greater comorbidities, and lower albumin. Seven studies reported reliability. While some instruments were feasible (CFS, Fatigue, Resistance, Ambulation, Illnesses, and Loss of Weight scale), their measurement could result in higher frailty prevalence compared with the PFP. Existing instruments do not capture the full spectrum of psychosocial and physiologic domains of frailty. CONCLUSIONS: The CFS demonstrates the strongest validity, apart from the PFP, although its use may result in higher measured frailty prevalence. Further research should test the feasibility of screening for frailty in clinical practice; the psychometric properties (i.e., responsiveness) of frailty instruments in younger adults, those with AKI, kidney transplant recipients, and those receiving conservative kidney management; and whether adding psychosocial and/or physiologic markers improves frailty measurement validity. Addressing these gaps will facilitate wider frailty measurement in kidney disease research and aid adoption into practice.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Nair D, Mittleman I, Magro J, et al. Frailty in Focus: A Scoping Review of Frailty Instruments from the Kidney Disease Aging Research Collaborative. Clin J Am Soc Nephrol. 2026. PMID: 41563838. doi:10.2215/CJN.0000000998

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。